News
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*
![](https://www.farmaindustriaticino.ch/files/2015/05/logo_zambon-160x160.png)
Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)
FIT premia il miglior lavoro di diploma nella Tecnica dei sistemi chimico-farmaceutica della SSST
![](https://www.farmaindustriaticino.ch/files/2019/04/helsinn-160x160.jpeg)
Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
![](https://www.farmaindustriaticino.ch/files/2019/04/helsinn-160x160.jpeg)
Verity PharmaceuticalsTM and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico
![](https://www.farmaindustriaticino.ch/files/2022/01/Logo-HAS-1-160x160.jpg)
HAS launches as an independent business
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Linkedin